Abstract
Conformationally constrained HIV-1 Env and gp120 immunogens induce broadly cross-reactive neutralizing antibodies. Thus, it is now feasible to rationally design an HIV-1 vaccine that affords protection through humoral mechanisms. This paper reviews our progress toward the development of an oral bacterial vaccine vector that is capable of delivering an HIV-1 DNA vaccine to host lymphoid tissues and inducing broadly neutralizing antibodies to HIV-1 in the mucosal and systemic immune compartments.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
AIDS Vaccines / immunology*
-
Administration, Oral
-
Animals
-
Bacterial Vaccines / genetics
-
Bacterial Vaccines / immunology*
-
Female
-
Gene Products, env / genetics
-
Gene Products, env / immunology*
-
Genetic Vectors*
-
HIV Antibodies / blood*
-
HIV Antibodies / immunology
-
HIV Envelope Protein gp120 / genetics
-
HIV Envelope Protein gp120 / immunology*
-
HIV-1 / immunology
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Neutralization Tests
-
Salmonella / genetics
-
Salmonella / immunology
-
Shigella / genetics
-
Shigella / immunology
Substances
-
AIDS Vaccines
-
Bacterial Vaccines
-
Gene Products, env
-
HIV Antibodies
-
HIV Envelope Protein gp120